<!DOCTYPE html>
<html lang="en">
	<head>
		<meta http-equiv="X-UA-Compatible" content="IE=edge">
		<meta http-equiv="content-type" content="text/html; charset=utf-8">

		<!-- Enable responsiveness on mobile devices-->
		<meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1">
		<title>blog</title>
		<link rel="shortcut icon" href="/pelican/theme/favicon/favicon.ico" />
		<link rel="stylesheet" href="/pelican/theme/css/poole.css" />
		<link rel="stylesheet" href="/pelican/theme/css/hyde.css" />
		<link rel="stylesheet" href="/pelican/theme/css/syntax.css" />
		<link rel="stylesheet" href="/pelican/theme/css/style.css" />
		<script type="text/javascript" src="/pelican/theme/css/all.js" />

		</script>
	</head>

	<body class="theme-base-0g">
	<div class="test-nav">
		<a href="/pelican">Home</a>
				<a href="/categories.html">Category</a>
				<a href="/tags.html">Tag</a>
	</div>
		<div class="content container">
<div class="post">
  <h2 class="post-title">coronavirus vaccine</h2>
	<span class="post-date">Sat 27 March 2021</span>
	<p>康希诺生物腺病毒新冠疫苗，只需要接种一针。</p>
<p>Ad5-nCoV，商品名为克威莎，是由<code>康希诺生物股份公司</code>[成立于2009年,总部天津]和<code>中国人民解放军军事科学院军事医学研究院生物工程研究所</code>[北京]开发的2019冠状病毒病疫苗，采用重组5型腺病毒载体，2020年下半年进入Ⅲ期临床试验阶段。Ad5-nCoV为陈薇团队研发，是目前中国批准上市的新冠疫苗中，唯一可采用单针接种程序的疫苗。</p>
<h4>Clinical trials [临床试验]</h4>
<p>Phase I-II</p>
<p>In early 2020, Chen Wei led a joint[联合的] team and <code>CanSino Biologics</code>[康希诺生物] to develop AD5-nCOV. According to the Chinese state media, the team registered an experimental COVID-19 vaccine for Phase I trial in China on 17 March 2020 to test its safety. The trial was conducted[实施] on 108 healthy adults aged 18 to 60 in two medical facilities[设施] in Wuhan, Hubei province.[20]</p>
<p>In April, Ad5-nCoV became the first COVID-19 vaccine candidate in the world to begin Phase II trials.The Phase II trial results were published in the <code>peer-reviewed journal Lancet</code>[同行评审杂志《柳叶刀》] on 20 July 2020 and noted <code>neutralizing antibody</code>[中和抗体] and T cell responses based on statistical analyses of data involving 508 eligible[有资格的] participants. In September, Zeng Guang said the amount of COVID-19 antibodies[抗体] in subjects from the Phase I trials remained high six months after the first shot[曾光说，I期试验受试者的COVID-19抗体在第一次注射后六个月仍然很高]. Zeng said the high levels of antibodies suggested the shots may provide immunity for an extended period of time, although Phase III results were still required. On September 24, CanSino began Phase IIb trials on 481 participants to evaluate the safety and immunogenicity of Ad5-nCoV for children ages 6–17 and elderly individuals ages 56 and above.</p>
<p>In August, China's National Intellectual Property Administration issued the country's first COVID-19 vaccine patent[专利] to CanSino.</p>
<p>On 16 May 2020, Canadian Prime Minister Justin Trudeau announced Health Canada had approved Phase II trials to be conducted by the Canadian Center for Vaccinology[疫苗学] (CCfV) on the COVID-19 vaccine produced[生产的] by CanSino. Scott Halperin, director of the CCfV said the vaccine would not be the only one going into clinical[临床] trials in Canada, and any potential[潜在的] vaccine would not be publicly available until after Phase 3 is complete. If the vaccine trials were successful, then the National Research Council would work with CanSino to produce and distribute the vaccine in Canada. In August 2020, the National Research Council disclosed[公开的] the vaccine had not been approved by Chinese customs[海关] to ship to Canada, after which the collaboration between CanSino and the Canadian Center for Vaccinology was abandoned.</p>
<h4>Nasal spray trials[鼻喷雾试验]</h4>
<p>In September, CanSino began a Phase I trial in China with 144 adults to determine the safety and immunogenicity of the vaccine to be administered[用药，只有被动形式 be administered to sb] as a nasal spray, in contrast with[与...相比] most COVID-19 vaccine candidates which require intramuscular[肌内] injection.</p>
<h4>Phase III</h4>
<p>In August, Saudi Arabia confirmed it would begin Phase III trials on 5,000 people for Ad5-nCoV in the cities of Riyadh, Dammam, and Mecca.</p>
<p>In October, Mexico received the first batch[批] of the vaccine for Phase III trials on 10,000 to 15,000 volunteers. Phase III trails were to be performed in Chihuahua, Durango, Nuevo León, Jalisco, Aguascalientes, Michoacán, Guerrero, Oaxaca, Morelos, Quintana Roo, Veracruz, Puebla, Hidalgo and Mexico City and began during the first week of November[十一月].</p>
<p>In September, Russia's NPO Petrovax began Phase III trials on 500 volunteers, which Petrovax[彼得罗瓦克斯] later received approval from the government to expand to 8,000 more volunteers.</p>
<p>In September, Pakistan began Phase III trials on 40,000 volunteers as part of a global multi-center study. As of December[截至十二月], about 13,000 volunteers have participated in trials of Ad5-nCoV.</p>
<p>In November, Chile approved Phase III trials on 5,200 volunteers to be managed by University of La Frontera[边界].</p>
<p>In December, Argentina[阿根廷]'s Fundación Hupedes began Phase III trials in 11 health centers in the metropolitan[大都市] area of Buenos Aires and Mar del Plata.</p>
<hr>
<ul>
<li>
<p>March 17, 2020 Phase I 108名18-60岁志愿者</p>
</li>
<li>
<p>July 20, 2020 Phase II 的508名志愿者测试结果发布在柳叶刀</p>
</li>
<li>
<p>September 24, 2020 再次进行Phase IIb trials, 针对ages 6–17和56及以上的481名志愿者</p>
</li>
</ul>
<hr>
<p>以下是康希诺cansinotech.com查询到的pdf资讯，我会按照时间的顺序来排序：</p>
<ul>
<li>
<p>Feb 1, 2021<br/>
  已完成Ad5-nCoV的III期临床试验中期分析的应计病例，这些数据已提交给独立数据监测委员会（“ IDMC”）进行分析和建议。IDMC已通知Ad5-nCoV在此中期分析中已成功满足其预先指定的主要安全性和有效性标准。<code>没有疫苗相关的严重不良事件（“ SAE”）</code>，因此公司可以继续推进Ad5-nCoV的III期临床试验。截至本公告发布之日，公司对参与试验的<u>参与者</u>是否已<code>接种疫苗</code>或<code>安慰剂</code><u>视而不见</u>。公司将在适当的时候就Ad5-nCoV的III期临床试验的详细信息和发展发表进一步的公告。<u>所有参与者都在第0天接受了单剂量的Ad5-nCoV或安慰剂疫苗，并将在52周内跟踪监测候选疫苗的功效和SAE的发生率。主要功效目标是Ad5-nCoV在预防接种后28天至52周内发生的病毒学确诊（PCR阳性）症状性COVID-19疾病中，无论其严重程度如何。将Ad5-nCoV组的COVID-19疾病发生率与对照组的COVID-19发生率进行比较。主要的安全目标是评估所有参与者接种疫苗后52周内SAE的发生率和医疗不良事件</u>。 Ad5-nCoV的III期临床试验已在三大洲五个国家/地区的78个临床试验地点为40,000多名志愿者进行了疫苗接种，由全球主要研究人员（PI），全球共同PI和来自国家的共同PI领导七个国家/地区，并严格遵守高道德标准和严格的科学原则。</p>
</li>
<li>
<p>Feb 9, 2021<br/>
  Ad5-nCoV已获墨西哥联邦卫生风险保护委员会批准在2021年2月9日（当地时间）紧急使用18年及以上。Ad5-nCoV的商品名为Convidecia™。</p>
</li>
<li>
<p>Feb 24, 2021<br/>
  本公司已为<code>重组新型冠状病毒疫苗</code>（本公司与军事医学科学院北京生物技术研究所在巴基斯坦，墨西哥，俄罗斯，智利和阿根廷等五个国家联合开发的5型腺病毒载体（“ Ad5-nCoV”，商品名：Convidecia™）。<u>公司已经完成了40,000多名志愿者的Ad5-nCoV的III期临床试验的中期分析数据，Ad5-nCoV单剂疫苗接种28天后预防所有有症状COVID-19疾病的总体疗效为65.28％，在预防所有有症状COVID-68的总体疗效为68.83％单剂疫苗接种后14天有19种疾病。 Ad5-nCoV在单剂疫苗接种后28天预防严重疾病的功效为90.07％，在单剂疫苗接种后14天预防严重疾病的功效为95.47％i</u>.Ad5-nCoV的功效已满足该法规制定的相关技术标准。世界卫生组织以及国家医疗产品管理局发布的“新型冠状病毒预防用疫苗临床评价指导原则（试行）”中规定的“新型冠状病毒预防疫苗临床评价指导原则（试行）*”中规定的相关标准和要求。 （“ NMPA”）。2021年2月21日，公司正式向NMPA提出了Ad5-nCoV的有条件营销授权申请，NMPA已接受该申请。<br/>公司于2021年2月24日签署了以下协议，其中包括（其中包括）国家医疗产品管理局（“ NMPA”）接受有条件的销售许可，用于重组COVID-19疫苗（腺病毒5型载体）（以下简称“ Ad5-nCoV”（商品名：Convidecia™）。公司高兴地宣布，NMPA已于2021年2月25日授予有条件的营销授权在中国大陆投放Ad5-nCoV  </p>
</li>
</ul>
<hr>
<p>国药集团及科兴生物3款灭活疫苗都需要接种2针。智飞生物重组疫苗需要接种3针。</p>
</div>
		</div>
	</body>
</html>